Amgen Inc. $AMGN Stock Position Lowered by Lansforsakringar Fondforvaltning AB publ

Lansforsakringar Fondforvaltning AB publ decreased its position in Amgen Inc. (NASDAQ:AMGN) by 12.3% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 172,718 shares of the medical research company’s stock after selling 24,304 shares during the period. Lansforsakringar Fondforvaltning AB publ’s holdings in Amgen were worth $60,771,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. grew its stake in Amgen by 10.0% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares in the last quarter. Curtis Advisory Group LLC purchased a new stake in shares of Amgen in the fourth quarter worth approximately $1,669,000. Adell Harriman & Carpenter Inc. lifted its position in shares of Amgen by 7.9% in the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after purchasing an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in shares of Amgen during the fourth quarter worth approximately $22,441,000. Finally, Robinhood Asset Management LLC purchased a new position in Amgen during the fourth quarter valued at approximately $17,526,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Stock Performance

Shares of AMGN opened at $360.55 on Tuesday. The company’s fifty day moving average is $340.92 and its 200-day moving average is $346.71. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The firm has a market cap of $194.59 billion, a price-to-earnings ratio of 25.09, a price-to-earnings-growth ratio of 3.60 and a beta of 0.42. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. Amgen’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts expect that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.85% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

AMGN has been the topic of several research reports. Morgan Stanley upped their price objective on shares of Amgen from $332.00 to $340.00 and gave the company an “equal weight” rating in a research note on Tuesday, June 9th. Argus decreased their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research note on Wednesday, May 20th. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. Wall Street Zen downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Erste Group Bank reiterated a “hold” rating on shares of Amgen in a report on Tuesday, May 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.